---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-002103"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:19:14.174276+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aptose shareholders approve Hanmi go-private at C$2.41/share; FY net loss $25.5M

## Summary
- Shareholders approved acquisition by Hanmi at C$2.41/share (28% premium over 30-day VWAP of C$1.88).
- 84.87% of non-Hanmi shares voted for the arrangement; Alberta court issued final order; closing expected by end of April 2026.
- FY2025 net loss $25.5M (flat vs $25.4M); cash $4.1M as of Dec 31, 2025; company notes insufficient cash to fund operations; relies on Hanmi advances.
- TUS+VEN+AZA triplet in newly diagnosed AML showed 90% CR/CRh, 78% MRD negativity by central flow; no dose-limiting toxicities.
- Hanmi provided over US$41M in debt facilities over past 18 months to support Aptose.

## SEC filing metadata
- accession: 0001171843-26-002103
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000117184326002103/0001171843-26-002103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000117184326002103/f8k_033126.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-002103
- JSON: https://secwatch.observer/filing/0001171843-26-002103.json
- Plain text: https://secwatch.observer/filing/0001171843-26-002103.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.